13P HER2 low testing in breast cancer: How to optimize detection

HER2 Testing in Invasive Breast Cancer: a Comparison between Immunohistochemistry and FISH Assays

HER2 Testing in Breast Cancer: Opportunities and Challenges

Zusammenfassung Der humane epidermale Wachstumsfaktor-Rezeptor-2 (HER2) wird in 15–25% der Mammakarzinome überexprimiert, üblicherweise auf dem Boden einer Genamplifikation. Ein positiver HER2-Status gilt als ungünstiger Prognosefaktor. Die Aufdeckung der Rolle von HER2 im Tumorwachstum des Mammakarzinoms hat zu der Entwicklung einer anti-HER2-gerichteten Therapie geführt. Der humanisierte mono...

Testing for HER2 in Breast Cancer: A Continuing Evolution

Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor in breast cancer. HER2 is overexpressed in approximately 15%-20% of invasive breast carcinomas and is associated with earlier recurrence, shortened disease free survival, and poor prognosis. Trastuzumab (Herceptin) a "humanized" monoclonal antibody targets the extracellular domain of HER2 and is wid...

How to optimize aesthetic outcomes in implant-based breast reconstruction

The evolution of breast reconstructive surgery keeps pace with the evolution of breast oncologic surgery. The reconstructive choice should always balance the optimal local control of disease and the best cosmetic result, reflecting an informed decision that is shared with the patient, who is always at the center of the decision-making process. Implant-based breast reconstruction following maste...

HER2-Positive Breast Cancer

• Objective: To review the diagnosis and management of HER2-positive breast cancer. • Methods: Qualitative review of the literature. • Results: Amplification of HER2 occurs in 20% to 25% of breast cancers and is associated with highgrade tumors that are poorly differentiated and have higher rates of recurrence. Trastuzumab, a recombinant humanized monoclonal antibody against the extracellular d...